Previous Page
API Technologies Corp. (NASDAQ: ATNY) announced the addition of high reliability MIL grade SMPS ceramic capacitors to its Spectrum Control product line. These high-speed switch mode power supply (SMPS) capacitors feature extremely low equivalent series resistance (ESR) and equivalent series inductance (ESL), as well as predictable performance characteristics with changes in temperature, voltage and frequency. They are ideal for high reliability and high frequency applications. A commercial industrial grade alternative in a non-military package configuration is also available. The company has also received a $8.1 million order for its Electronics Manufacturing Services (EMS) business unit to provide electronics solutions for tactical surveillance systems. The order was placed by a Fortune 100 company repeat customer and is scheduled to be delivered over the next nine months. http://www.apitech.com
Attolight announces that it has raised CHF 1.5m from both institutional and private investors: these include Aargauische Kantonalbank, Zürcher Kantonalbank, StartAngels Network and Verve Capital Partners. The active participation of the existing investors in this 2nd financing round reinforces their confidence in Attolight.
Leti is announcing a new collaboration with the Swiss company Attolight to develop cathodoluminescence technology for more applications. Attolight’s innovative technology combines electron and light microscopy to reveal ultra-trace impurities and crystallographic defects that are not visible using other imaging techniques.
http://www.leti.fr http://www.attolight.com/
Arrowhead Research Corporation (NASDAQ: ARWR) received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application US 13/032,029 entitled, "Compositions for Targeted Delivery of siRNA." The patent broadly covers compositions, methods, and uses for a new formulation of Arrowhead’s Dynamic Polyconjugate (DPC) siRNA delivery platform, where attachment of siRNA and delivery vehicle is not required to produce high-level, efficient knockdown of target genes. The new IP expands the DPC platform and is used in Arrowhead’s ARC-520 candidate in development for chronic hepatitis B virus (HBV) infection.